nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydromorphone—CYP3A4—bone cancer	0.787	1	CbGaD
Hydromorphone—Dihydrocodeine—CYP3A4—bone cancer	0.00116	0.154	CrCbGaD
Hydromorphone—Oxymorphone—CYP3A4—bone cancer	0.00101	0.135	CrCbGaD
Hydromorphone—Ethylmorphine—CYP3A4—bone cancer	0.000969	0.129	CrCbGaD
Hydromorphone—Hydrocodone—CYP3A4—bone cancer	0.000886	0.118	CrCbGaD
Hydromorphone—Oxycodone—CYP3A4—bone cancer	0.000809	0.108	CrCbGaD
Hydromorphone—Codeine—CYP3A4—bone cancer	0.000771	0.103	CrCbGaD
Hydromorphone—Naloxone—CYP3A4—bone cancer	0.00074	0.0987	CrCbGaD
Hydromorphone—Morphine—CYP3A4—bone cancer	0.000624	0.0833	CrCbGaD
Hydromorphone—Dextromethorphan—CYP3A4—bone cancer	0.000524	0.07	CrCbGaD
Hydromorphone—UGT1A9—Irinotecan Pathway—CYP3A4—bone cancer	0.000508	0.0464	CbGpPWpGaD
Hydromorphone—UGT1A9—Estrogen metabolism—CYP3A4—bone cancer	0.000415	0.0379	CbGpPWpGaD
Hydromorphone—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000343	0.0314	CbGpPWpGaD
Hydromorphone—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000342	0.0312	CbGpPWpGaD
Hydromorphone—UGT1A9—Metapathway biotransformation—CYP4V2—bone cancer	0.00034	0.0311	CbGpPWpGaD
Hydromorphone—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000339	0.031	CbGpPWpGaD
Hydromorphone—Pollakiuria—Epirubicin—bone cancer	0.000331	0.0017	CcSEcCtD
Hydromorphone—Sweating—Methotrexate—bone cancer	0.000327	0.00168	CcSEcCtD
Hydromorphone—Feeling abnormal—Cisplatin—bone cancer	0.000327	0.00168	CcSEcCtD
Hydromorphone—Weight decreased—Epirubicin—bone cancer	0.000324	0.00167	CcSEcCtD
Hydromorphone—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000324	0.0296	CbGpPWpGaD
Hydromorphone—Hepatobiliary disease—Methotrexate—bone cancer	0.000323	0.00166	CcSEcCtD
Hydromorphone—Infestation NOS—Epirubicin—bone cancer	0.00032	0.00164	CcSEcCtD
Hydromorphone—Infestation—Epirubicin—bone cancer	0.00032	0.00164	CcSEcCtD
Hydromorphone—Drowsiness—Epirubicin—bone cancer	0.00032	0.00164	CcSEcCtD
Hydromorphone—Body temperature increased—Cisplatin—bone cancer	0.000314	0.00161	CcSEcCtD
Hydromorphone—Stomatitis—Epirubicin—bone cancer	0.000311	0.0016	CcSEcCtD
Hydromorphone—Dysuria—Doxorubicin—bone cancer	0.00031	0.00159	CcSEcCtD
Hydromorphone—Sweating—Epirubicin—bone cancer	0.000306	0.00157	CcSEcCtD
Hydromorphone—Pollakiuria—Doxorubicin—bone cancer	0.000306	0.00157	CcSEcCtD
Hydromorphone—Urinary tract disorder—Methotrexate—bone cancer	0.000303	0.00155	CcSEcCtD
Hydromorphone—Hepatobiliary disease—Epirubicin—bone cancer	0.000302	0.00155	CcSEcCtD
Hydromorphone—Urethral disorder—Methotrexate—bone cancer	0.0003	0.00154	CcSEcCtD
Hydromorphone—Weight decreased—Doxorubicin—bone cancer	0.0003	0.00154	CcSEcCtD
Hydromorphone—Infestation—Doxorubicin—bone cancer	0.000296	0.00152	CcSEcCtD
Hydromorphone—Infestation NOS—Doxorubicin—bone cancer	0.000296	0.00152	CcSEcCtD
Hydromorphone—Drowsiness—Doxorubicin—bone cancer	0.000296	0.00152	CcSEcCtD
Hydromorphone—Visual impairment—Methotrexate—bone cancer	0.000295	0.00152	CcSEcCtD
Hydromorphone—Hypersensitivity—Cisplatin—bone cancer	0.000292	0.0015	CcSEcCtD
Hydromorphone—Bradycardia—Epirubicin—bone cancer	0.000292	0.0015	CcSEcCtD
Hydromorphone—Stomatitis—Doxorubicin—bone cancer	0.000288	0.00148	CcSEcCtD
Hydromorphone—Rhinitis—Epirubicin—bone cancer	0.000288	0.00148	CcSEcCtD
Hydromorphone—Eye disorder—Methotrexate—bone cancer	0.000286	0.00147	CcSEcCtD
Hydromorphone—Tinnitus—Methotrexate—bone cancer	0.000286	0.00147	CcSEcCtD
Hydromorphone—Hypoaesthesia—Epirubicin—bone cancer	0.000285	0.00147	CcSEcCtD
Hydromorphone—Asthenia—Cisplatin—bone cancer	0.000285	0.00146	CcSEcCtD
Hydromorphone—Cardiac disorder—Methotrexate—bone cancer	0.000284	0.00146	CcSEcCtD
Hydromorphone—Sweating—Doxorubicin—bone cancer	0.000283	0.00146	CcSEcCtD
Hydromorphone—Urinary tract disorder—Epirubicin—bone cancer	0.000283	0.00145	CcSEcCtD
Hydromorphone—Oedema peripheral—Epirubicin—bone cancer	0.000283	0.00145	CcSEcCtD
Hydromorphone—Connective tissue disorder—Epirubicin—bone cancer	0.000282	0.00145	CcSEcCtD
Hydromorphone—Urethral disorder—Epirubicin—bone cancer	0.000281	0.00144	CcSEcCtD
Hydromorphone—Hepatobiliary disease—Doxorubicin—bone cancer	0.00028	0.00144	CcSEcCtD
Hydromorphone—Angiopathy—Methotrexate—bone cancer	0.000278	0.00143	CcSEcCtD
Hydromorphone—Immune system disorder—Methotrexate—bone cancer	0.000277	0.00142	CcSEcCtD
Hydromorphone—Visual impairment—Epirubicin—bone cancer	0.000276	0.00142	CcSEcCtD
Hydromorphone—Mediastinal disorder—Methotrexate—bone cancer	0.000276	0.00142	CcSEcCtD
Hydromorphone—Chills—Methotrexate—bone cancer	0.000275	0.00141	CcSEcCtD
Hydromorphone—Diarrhoea—Cisplatin—bone cancer	0.000272	0.00139	CcSEcCtD
Hydromorphone—Bradycardia—Doxorubicin—bone cancer	0.00027	0.00139	CcSEcCtD
Hydromorphone—Mental disorder—Methotrexate—bone cancer	0.000269	0.00138	CcSEcCtD
Hydromorphone—Eye disorder—Epirubicin—bone cancer	0.000268	0.00138	CcSEcCtD
Hydromorphone—Tinnitus—Epirubicin—bone cancer	0.000267	0.00137	CcSEcCtD
Hydromorphone—Erythema—Methotrexate—bone cancer	0.000267	0.00137	CcSEcCtD
Hydromorphone—Malnutrition—Methotrexate—bone cancer	0.000267	0.00137	CcSEcCtD
Hydromorphone—Flushing—Epirubicin—bone cancer	0.000266	0.00137	CcSEcCtD
Hydromorphone—Cardiac disorder—Epirubicin—bone cancer	0.000266	0.00137	CcSEcCtD
Hydromorphone—Rhinitis—Doxorubicin—bone cancer	0.000266	0.00137	CcSEcCtD
Hydromorphone—Hypoaesthesia—Doxorubicin—bone cancer	0.000264	0.00136	CcSEcCtD
Hydromorphone—Urinary tract disorder—Doxorubicin—bone cancer	0.000262	0.00135	CcSEcCtD
Hydromorphone—UGT1A9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000262	0.0239	CbGpPWpGaD
Hydromorphone—Oedema peripheral—Doxorubicin—bone cancer	0.000261	0.00134	CcSEcCtD
Hydromorphone—Dysgeusia—Methotrexate—bone cancer	0.000261	0.00134	CcSEcCtD
Hydromorphone—Connective tissue disorder—Doxorubicin—bone cancer	0.000261	0.00134	CcSEcCtD
Hydromorphone—Angiopathy—Epirubicin—bone cancer	0.00026	0.00134	CcSEcCtD
Hydromorphone—Urethral disorder—Doxorubicin—bone cancer	0.00026	0.00134	CcSEcCtD
Hydromorphone—Immune system disorder—Epirubicin—bone cancer	0.000259	0.00133	CcSEcCtD
Hydromorphone—Mediastinal disorder—Epirubicin—bone cancer	0.000259	0.00133	CcSEcCtD
Hydromorphone—Back pain—Methotrexate—bone cancer	0.000258	0.00133	CcSEcCtD
Hydromorphone—Chills—Epirubicin—bone cancer	0.000257	0.00132	CcSEcCtD
Hydromorphone—Arrhythmia—Epirubicin—bone cancer	0.000256	0.00132	CcSEcCtD
Hydromorphone—Visual impairment—Doxorubicin—bone cancer	0.000256	0.00131	CcSEcCtD
Hydromorphone—Vomiting—Cisplatin—bone cancer	0.000252	0.0013	CcSEcCtD
Hydromorphone—Vision blurred—Methotrexate—bone cancer	0.000251	0.00129	CcSEcCtD
Hydromorphone—Mental disorder—Epirubicin—bone cancer	0.000251	0.00129	CcSEcCtD
Hydromorphone—Rash—Cisplatin—bone cancer	0.00025	0.00128	CcSEcCtD
Hydromorphone—Dermatitis—Cisplatin—bone cancer	0.00025	0.00128	CcSEcCtD
Hydromorphone—Erythema—Epirubicin—bone cancer	0.00025	0.00128	CcSEcCtD
Hydromorphone—Malnutrition—Epirubicin—bone cancer	0.00025	0.00128	CcSEcCtD
Hydromorphone—Eye disorder—Doxorubicin—bone cancer	0.000248	0.00127	CcSEcCtD
Hydromorphone—Ill-defined disorder—Methotrexate—bone cancer	0.000248	0.00127	CcSEcCtD
Hydromorphone—Tinnitus—Doxorubicin—bone cancer	0.000247	0.00127	CcSEcCtD
Hydromorphone—Cardiac disorder—Doxorubicin—bone cancer	0.000246	0.00126	CcSEcCtD
Hydromorphone—Flushing—Doxorubicin—bone cancer	0.000246	0.00126	CcSEcCtD
Hydromorphone—Flatulence—Epirubicin—bone cancer	0.000246	0.00126	CcSEcCtD
Hydromorphone—Tension—Epirubicin—bone cancer	0.000245	0.00126	CcSEcCtD
Hydromorphone—Dysgeusia—Epirubicin—bone cancer	0.000245	0.00126	CcSEcCtD
Hydromorphone—Nervousness—Epirubicin—bone cancer	0.000243	0.00125	CcSEcCtD
Hydromorphone—Back pain—Epirubicin—bone cancer	0.000242	0.00124	CcSEcCtD
Hydromorphone—Angiopathy—Doxorubicin—bone cancer	0.000241	0.00124	CcSEcCtD
Hydromorphone—OPRK1—Mecp2 and Associated Rett Syndrome—EZH2—bone cancer	0.000241	0.022	CbGpPWpGaD
Hydromorphone—Malaise—Methotrexate—bone cancer	0.000241	0.00124	CcSEcCtD
Hydromorphone—Muscle spasms—Epirubicin—bone cancer	0.00024	0.00123	CcSEcCtD
Hydromorphone—Immune system disorder—Doxorubicin—bone cancer	0.00024	0.00123	CcSEcCtD
Hydromorphone—Vertigo—Methotrexate—bone cancer	0.00024	0.00123	CcSEcCtD
Hydromorphone—Mediastinal disorder—Doxorubicin—bone cancer	0.000239	0.00123	CcSEcCtD
Hydromorphone—Leukopenia—Methotrexate—bone cancer	0.000239	0.00123	CcSEcCtD
Hydromorphone—Chills—Doxorubicin—bone cancer	0.000238	0.00122	CcSEcCtD
Hydromorphone—Arrhythmia—Doxorubicin—bone cancer	0.000237	0.00122	CcSEcCtD
Hydromorphone—Nausea—Cisplatin—bone cancer	0.000236	0.00121	CcSEcCtD
Hydromorphone—Vision blurred—Epirubicin—bone cancer	0.000235	0.00121	CcSEcCtD
Hydromorphone—Cough—Methotrexate—bone cancer	0.000233	0.0012	CcSEcCtD
Hydromorphone—Mental disorder—Doxorubicin—bone cancer	0.000233	0.00119	CcSEcCtD
Hydromorphone—Ill-defined disorder—Epirubicin—bone cancer	0.000232	0.00119	CcSEcCtD
Hydromorphone—Convulsion—Methotrexate—bone cancer	0.000231	0.00119	CcSEcCtD
Hydromorphone—Malnutrition—Doxorubicin—bone cancer	0.000231	0.00119	CcSEcCtD
Hydromorphone—Erythema—Doxorubicin—bone cancer	0.000231	0.00119	CcSEcCtD
Hydromorphone—Agitation—Epirubicin—bone cancer	0.000229	0.00118	CcSEcCtD
Hydromorphone—Flatulence—Doxorubicin—bone cancer	0.000228	0.00117	CcSEcCtD
Hydromorphone—Chest pain—Methotrexate—bone cancer	0.000227	0.00117	CcSEcCtD
Hydromorphone—Myalgia—Methotrexate—bone cancer	0.000227	0.00117	CcSEcCtD
Hydromorphone—Arthralgia—Methotrexate—bone cancer	0.000227	0.00117	CcSEcCtD
Hydromorphone—Tension—Doxorubicin—bone cancer	0.000227	0.00116	CcSEcCtD
Hydromorphone—Dysgeusia—Doxorubicin—bone cancer	0.000226	0.00116	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000226	0.00116	CcSEcCtD
Hydromorphone—Malaise—Epirubicin—bone cancer	0.000225	0.00116	CcSEcCtD
Hydromorphone—Discomfort—Methotrexate—bone cancer	0.000224	0.00115	CcSEcCtD
Hydromorphone—Nervousness—Doxorubicin—bone cancer	0.000224	0.00115	CcSEcCtD
Hydromorphone—Vertigo—Epirubicin—bone cancer	0.000224	0.00115	CcSEcCtD
Hydromorphone—Syncope—Epirubicin—bone cancer	0.000224	0.00115	CcSEcCtD
Hydromorphone—Leukopenia—Epirubicin—bone cancer	0.000224	0.00115	CcSEcCtD
Hydromorphone—Back pain—Doxorubicin—bone cancer	0.000224	0.00115	CcSEcCtD
Hydromorphone—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000223	0.0204	CbGpPWpGaD
Hydromorphone—Muscle spasms—Doxorubicin—bone cancer	0.000222	0.00114	CcSEcCtD
Hydromorphone—Palpitations—Epirubicin—bone cancer	0.000221	0.00113	CcSEcCtD
Hydromorphone—Confusional state—Methotrexate—bone cancer	0.00022	0.00113	CcSEcCtD
Hydromorphone—Loss of consciousness—Epirubicin—bone cancer	0.000219	0.00113	CcSEcCtD
Hydromorphone—Cough—Epirubicin—bone cancer	0.000218	0.00112	CcSEcCtD
Hydromorphone—Anaphylactic shock—Methotrexate—bone cancer	0.000218	0.00112	CcSEcCtD
Hydromorphone—Vision blurred—Doxorubicin—bone cancer	0.000218	0.00112	CcSEcCtD
Hydromorphone—Convulsion—Epirubicin—bone cancer	0.000216	0.00111	CcSEcCtD
Hydromorphone—Infection—Methotrexate—bone cancer	0.000216	0.00111	CcSEcCtD
Hydromorphone—Hypertension—Epirubicin—bone cancer	0.000216	0.00111	CcSEcCtD
Hydromorphone—Ill-defined disorder—Doxorubicin—bone cancer	0.000214	0.0011	CcSEcCtD
Hydromorphone—Nervous system disorder—Methotrexate—bone cancer	0.000214	0.0011	CcSEcCtD
Hydromorphone—Chest pain—Epirubicin—bone cancer	0.000213	0.00109	CcSEcCtD
Hydromorphone—Arthralgia—Epirubicin—bone cancer	0.000213	0.00109	CcSEcCtD
Hydromorphone—Myalgia—Epirubicin—bone cancer	0.000213	0.00109	CcSEcCtD
Hydromorphone—Agitation—Doxorubicin—bone cancer	0.000212	0.00109	CcSEcCtD
Hydromorphone—Anxiety—Epirubicin—bone cancer	0.000212	0.00109	CcSEcCtD
Hydromorphone—Skin disorder—Methotrexate—bone cancer	0.000212	0.00109	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000211	0.00108	CcSEcCtD
Hydromorphone—Hyperhidrosis—Methotrexate—bone cancer	0.000211	0.00108	CcSEcCtD
Hydromorphone—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00021	0.0192	CbGpPWpGaD
Hydromorphone—Discomfort—Epirubicin—bone cancer	0.00021	0.00108	CcSEcCtD
Hydromorphone—Malaise—Doxorubicin—bone cancer	0.000208	0.00107	CcSEcCtD
Hydromorphone—Dry mouth—Epirubicin—bone cancer	0.000208	0.00107	CcSEcCtD
Hydromorphone—Vertigo—Doxorubicin—bone cancer	0.000208	0.00107	CcSEcCtD
Hydromorphone—Anorexia—Methotrexate—bone cancer	0.000208	0.00107	CcSEcCtD
Hydromorphone—Syncope—Doxorubicin—bone cancer	0.000207	0.00106	CcSEcCtD
Hydromorphone—Leukopenia—Doxorubicin—bone cancer	0.000207	0.00106	CcSEcCtD
Hydromorphone—Confusional state—Epirubicin—bone cancer	0.000206	0.00106	CcSEcCtD
Hydromorphone—Palpitations—Doxorubicin—bone cancer	0.000204	0.00105	CcSEcCtD
Hydromorphone—Anaphylactic shock—Epirubicin—bone cancer	0.000204	0.00105	CcSEcCtD
Hydromorphone—Hypotension—Methotrexate—bone cancer	0.000204	0.00104	CcSEcCtD
Hydromorphone—Loss of consciousness—Doxorubicin—bone cancer	0.000203	0.00104	CcSEcCtD
Hydromorphone—Infection—Epirubicin—bone cancer	0.000202	0.00104	CcSEcCtD
Hydromorphone—Cough—Doxorubicin—bone cancer	0.000202	0.00104	CcSEcCtD
Hydromorphone—Shock—Epirubicin—bone cancer	0.000201	0.00103	CcSEcCtD
Hydromorphone—Convulsion—Doxorubicin—bone cancer	0.0002	0.00103	CcSEcCtD
Hydromorphone—Nervous system disorder—Epirubicin—bone cancer	0.0002	0.00103	CcSEcCtD
Hydromorphone—Hypertension—Doxorubicin—bone cancer	0.000199	0.00102	CcSEcCtD
Hydromorphone—Tachycardia—Epirubicin—bone cancer	0.000199	0.00102	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000198	0.00102	CcSEcCtD
Hydromorphone—Skin disorder—Epirubicin—bone cancer	0.000198	0.00102	CcSEcCtD
Hydromorphone—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000197	0.018	CbGpPWpGaD
Hydromorphone—Hyperhidrosis—Epirubicin—bone cancer	0.000197	0.00101	CcSEcCtD
Hydromorphone—Insomnia—Methotrexate—bone cancer	0.000197	0.00101	CcSEcCtD
Hydromorphone—Chest pain—Doxorubicin—bone cancer	0.000197	0.00101	CcSEcCtD
Hydromorphone—Arthralgia—Doxorubicin—bone cancer	0.000197	0.00101	CcSEcCtD
Hydromorphone—Myalgia—Doxorubicin—bone cancer	0.000197	0.00101	CcSEcCtD
Hydromorphone—Anxiety—Doxorubicin—bone cancer	0.000196	0.00101	CcSEcCtD
Hydromorphone—Paraesthesia—Methotrexate—bone cancer	0.000196	0.001	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000195	0.001	CcSEcCtD
Hydromorphone—Discomfort—Doxorubicin—bone cancer	0.000194	0.000998	CcSEcCtD
Hydromorphone—Anorexia—Epirubicin—bone cancer	0.000194	0.000998	CcSEcCtD
Hydromorphone—Dyspnoea—Methotrexate—bone cancer	0.000194	0.000997	CcSEcCtD
Hydromorphone—Somnolence—Methotrexate—bone cancer	0.000194	0.000994	CcSEcCtD
Hydromorphone—Dry mouth—Doxorubicin—bone cancer	0.000192	0.000988	CcSEcCtD
Hydromorphone—UGT1A9—PPAR Alpha Pathway—CDK4—bone cancer	0.000192	0.0175	CbGpPWpGaD
Hydromorphone—Dyspepsia—Methotrexate—bone cancer	0.000192	0.000984	CcSEcCtD
Hydromorphone—Hypotension—Epirubicin—bone cancer	0.00019	0.000978	CcSEcCtD
Hydromorphone—Confusional state—Doxorubicin—bone cancer	0.00019	0.000976	CcSEcCtD
Hydromorphone—Decreased appetite—Methotrexate—bone cancer	0.000189	0.000972	CcSEcCtD
Hydromorphone—Anaphylactic shock—Doxorubicin—bone cancer	0.000189	0.000968	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Methotrexate—bone cancer	0.000188	0.000965	CcSEcCtD
Hydromorphone—Fatigue—Methotrexate—bone cancer	0.000188	0.000964	CcSEcCtD
Hydromorphone—Infection—Doxorubicin—bone cancer	0.000187	0.000962	CcSEcCtD
Hydromorphone—Pain—Methotrexate—bone cancer	0.000186	0.000956	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000186	0.000953	CcSEcCtD
Hydromorphone—Shock—Doxorubicin—bone cancer	0.000186	0.000953	CcSEcCtD
Hydromorphone—Nervous system disorder—Doxorubicin—bone cancer	0.000185	0.00095	CcSEcCtD
Hydromorphone—Insomnia—Epirubicin—bone cancer	0.000184	0.000947	CcSEcCtD
Hydromorphone—Tachycardia—Doxorubicin—bone cancer	0.000184	0.000945	CcSEcCtD
Hydromorphone—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000183	0.0168	CbGpPWpGaD
Hydromorphone—Skin disorder—Doxorubicin—bone cancer	0.000183	0.000941	CcSEcCtD
Hydromorphone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000183	0.0167	CbGpPWpGaD
Hydromorphone—Paraesthesia—Epirubicin—bone cancer	0.000183	0.00094	CcSEcCtD
Hydromorphone—Hyperhidrosis—Doxorubicin—bone cancer	0.000182	0.000936	CcSEcCtD
Hydromorphone—Dyspnoea—Epirubicin—bone cancer	0.000182	0.000933	CcSEcCtD
Hydromorphone—Somnolence—Epirubicin—bone cancer	0.000181	0.00093	CcSEcCtD
Hydromorphone—Anorexia—Doxorubicin—bone cancer	0.00018	0.000923	CcSEcCtD
Hydromorphone—Feeling abnormal—Methotrexate—bone cancer	0.000179	0.000922	CcSEcCtD
Hydromorphone—Dyspepsia—Epirubicin—bone cancer	0.000179	0.000921	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Methotrexate—bone cancer	0.000178	0.000914	CcSEcCtD
Hydromorphone—Decreased appetite—Epirubicin—bone cancer	0.000177	0.00091	CcSEcCtD
Hydromorphone—Hypotension—Doxorubicin—bone cancer	0.000176	0.000905	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Epirubicin—bone cancer	0.000176	0.000904	CcSEcCtD
Hydromorphone—Fatigue—Epirubicin—bone cancer	0.000176	0.000902	CcSEcCtD
Hydromorphone—Constipation—Epirubicin—bone cancer	0.000174	0.000895	CcSEcCtD
Hydromorphone—Pain—Epirubicin—bone cancer	0.000174	0.000895	CcSEcCtD
Hydromorphone—Urticaria—Methotrexate—bone cancer	0.000173	0.000888	CcSEcCtD
Hydromorphone—Body temperature increased—Methotrexate—bone cancer	0.000172	0.000884	CcSEcCtD
Hydromorphone—Abdominal pain—Methotrexate—bone cancer	0.000172	0.000884	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000172	0.000882	CcSEcCtD
Hydromorphone—Insomnia—Doxorubicin—bone cancer	0.000171	0.000876	CcSEcCtD
Hydromorphone—Paraesthesia—Doxorubicin—bone cancer	0.000169	0.00087	CcSEcCtD
Hydromorphone—Dyspnoea—Doxorubicin—bone cancer	0.000168	0.000863	CcSEcCtD
Hydromorphone—Feeling abnormal—Epirubicin—bone cancer	0.000168	0.000862	CcSEcCtD
Hydromorphone—Somnolence—Doxorubicin—bone cancer	0.000168	0.000861	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Epirubicin—bone cancer	0.000167	0.000856	CcSEcCtD
Hydromorphone—Dyspepsia—Doxorubicin—bone cancer	0.000166	0.000852	CcSEcCtD
Hydromorphone—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000165	0.0151	CbGpPWpGaD
Hydromorphone—Decreased appetite—Doxorubicin—bone cancer	0.000164	0.000842	CcSEcCtD
Hydromorphone—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000164	0.0149	CbGpPWpGaD
Hydromorphone—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000163	0.000836	CcSEcCtD
Hydromorphone—Fatigue—Doxorubicin—bone cancer	0.000163	0.000835	CcSEcCtD
Hydromorphone—Urticaria—Epirubicin—bone cancer	0.000162	0.000831	CcSEcCtD
Hydromorphone—Pain—Doxorubicin—bone cancer	0.000161	0.000828	CcSEcCtD
Hydromorphone—Constipation—Doxorubicin—bone cancer	0.000161	0.000828	CcSEcCtD
Hydromorphone—Abdominal pain—Epirubicin—bone cancer	0.000161	0.000827	CcSEcCtD
Hydromorphone—Body temperature increased—Epirubicin—bone cancer	0.000161	0.000827	CcSEcCtD
Hydromorphone—Hypersensitivity—Methotrexate—bone cancer	0.00016	0.000824	CcSEcCtD
Hydromorphone—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000159	0.0145	CbGpPWpGaD
Hydromorphone—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000157	0.0144	CbGpPWpGaD
Hydromorphone—Asthenia—Methotrexate—bone cancer	0.000156	0.000802	CcSEcCtD
Hydromorphone—Feeling abnormal—Doxorubicin—bone cancer	0.000155	0.000798	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Doxorubicin—bone cancer	0.000154	0.000792	CcSEcCtD
Hydromorphone—Pruritus—Methotrexate—bone cancer	0.000154	0.000791	CcSEcCtD
Hydromorphone—Hypersensitivity—Epirubicin—bone cancer	0.00015	0.000771	CcSEcCtD
Hydromorphone—Urticaria—Doxorubicin—bone cancer	0.00015	0.000769	CcSEcCtD
Hydromorphone—Abdominal pain—Doxorubicin—bone cancer	0.000149	0.000766	CcSEcCtD
Hydromorphone—Body temperature increased—Doxorubicin—bone cancer	0.000149	0.000766	CcSEcCtD
Hydromorphone—Diarrhoea—Methotrexate—bone cancer	0.000149	0.000765	CcSEcCtD
Hydromorphone—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000147	0.0134	CbGpPWpGaD
Hydromorphone—Asthenia—Epirubicin—bone cancer	0.000146	0.000751	CcSEcCtD
Hydromorphone—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000146	0.0133	CbGpPWpGaD
Hydromorphone—Pruritus—Epirubicin—bone cancer	0.000144	0.00074	CcSEcCtD
Hydromorphone—Dizziness—Methotrexate—bone cancer	0.000144	0.00074	CcSEcCtD
Hydromorphone—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000144	0.0131	CbGpPWpGaD
Hydromorphone—Diarrhoea—Epirubicin—bone cancer	0.000139	0.000716	CcSEcCtD
Hydromorphone—Hypersensitivity—Doxorubicin—bone cancer	0.000139	0.000713	CcSEcCtD
Hydromorphone—Vomiting—Methotrexate—bone cancer	0.000138	0.000711	CcSEcCtD
Hydromorphone—OPRD1—G alpha (i) signalling events—RGS1—bone cancer	0.000138	0.0127	CbGpPWpGaD
Hydromorphone—OPRD1—G alpha (i) signalling events—GRM4—bone cancer	0.000138	0.0127	CbGpPWpGaD
Hydromorphone—Rash—Methotrexate—bone cancer	0.000137	0.000705	CcSEcCtD
Hydromorphone—Dermatitis—Methotrexate—bone cancer	0.000137	0.000704	CcSEcCtD
Hydromorphone—Headache—Methotrexate—bone cancer	0.000136	0.000701	CcSEcCtD
Hydromorphone—Asthenia—Doxorubicin—bone cancer	0.000135	0.000695	CcSEcCtD
Hydromorphone—Dizziness—Epirubicin—bone cancer	0.000135	0.000692	CcSEcCtD
Hydromorphone—Pruritus—Doxorubicin—bone cancer	0.000133	0.000685	CcSEcCtD
Hydromorphone—Vomiting—Epirubicin—bone cancer	0.00013	0.000665	CcSEcCtD
Hydromorphone—Nausea—Methotrexate—bone cancer	0.000129	0.000664	CcSEcCtD
Hydromorphone—Diarrhoea—Doxorubicin—bone cancer	0.000129	0.000663	CcSEcCtD
Hydromorphone—Rash—Epirubicin—bone cancer	0.000129	0.00066	CcSEcCtD
Hydromorphone—Dermatitis—Epirubicin—bone cancer	0.000128	0.000659	CcSEcCtD
Hydromorphone—Headache—Epirubicin—bone cancer	0.000128	0.000656	CcSEcCtD
Hydromorphone—Dizziness—Doxorubicin—bone cancer	0.000125	0.00064	CcSEcCtD
Hydromorphone—OPRK1—G alpha (i) signalling events—RGS1—bone cancer	0.000121	0.0111	CbGpPWpGaD
Hydromorphone—OPRK1—G alpha (i) signalling events—GRM4—bone cancer	0.000121	0.0111	CbGpPWpGaD
Hydromorphone—Nausea—Epirubicin—bone cancer	0.000121	0.000622	CcSEcCtD
Hydromorphone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000121	0.011	CbGpPWpGaD
Hydromorphone—Vomiting—Doxorubicin—bone cancer	0.00012	0.000616	CcSEcCtD
Hydromorphone—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000119	0.0109	CbGpPWpGaD
Hydromorphone—Rash—Doxorubicin—bone cancer	0.000119	0.000611	CcSEcCtD
Hydromorphone—Dermatitis—Doxorubicin—bone cancer	0.000119	0.00061	CcSEcCtD
Hydromorphone—Headache—Doxorubicin—bone cancer	0.000118	0.000607	CcSEcCtD
Hydromorphone—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000112	0.0103	CbGpPWpGaD
Hydromorphone—Nausea—Doxorubicin—bone cancer	0.000112	0.000575	CcSEcCtD
Hydromorphone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000107	0.00978	CbGpPWpGaD
Hydromorphone—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000105	0.00957	CbGpPWpGaD
Hydromorphone—OPRM1—G alpha (i) signalling events—GRM4—bone cancer	0.000103	0.00938	CbGpPWpGaD
Hydromorphone—OPRM1—G alpha (i) signalling events—RGS1—bone cancer	0.000103	0.00938	CbGpPWpGaD
Hydromorphone—UGT1A9—Phase II conjugation—GSTP1—bone cancer	9.97e-05	0.00912	CbGpPWpGaD
Hydromorphone—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	9.96e-05	0.00911	CbGpPWpGaD
Hydromorphone—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	9.62e-05	0.00879	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR ligand binding—GRM4—bone cancer	8.38e-05	0.00766	CbGpPWpGaD
Hydromorphone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	7.83e-05	0.00716	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR ligand binding—GRM4—bone cancer	7.35e-05	0.00672	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR ligand binding—GRM1—bone cancer	7.27e-05	0.00664	CbGpPWpGaD
Hydromorphone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	6.85e-05	0.00626	CbGpPWpGaD
Hydromorphone—UGT1A9—Biological oxidations—CYP3A4—bone cancer	6.82e-05	0.00624	CbGpPWpGaD
Hydromorphone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	6.79e-05	0.00621	CbGpPWpGaD
Hydromorphone—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	6.76e-05	0.00618	CbGpPWpGaD
Hydromorphone—UGT1A9—Metapathway biotransformation—CYP3A4—bone cancer	6.73e-05	0.00615	CbGpPWpGaD
Hydromorphone—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	6.7e-05	0.00613	CbGpPWpGaD
Hydromorphone—UGT1A9—NRF2 pathway—TGFBR2—bone cancer	6.65e-05	0.00608	CbGpPWpGaD
Hydromorphone—UGT1A9—NRF2 pathway—GSTP1—bone cancer	6.65e-05	0.00608	CbGpPWpGaD
Hydromorphone—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	6.62e-05	0.00605	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR ligand binding—GRM1—bone cancer	6.37e-05	0.00583	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR ligand binding—GRM4—bone cancer	6.21e-05	0.00568	CbGpPWpGaD
Hydromorphone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	6.16e-05	0.00563	CbGpPWpGaD
Hydromorphone—UGT1A9—Biological oxidations—GSTP1—bone cancer	5.84e-05	0.00533	CbGpPWpGaD
Hydromorphone—UGT1A9—Metapathway biotransformation—GSTP1—bone cancer	5.76e-05	0.00526	CbGpPWpGaD
Hydromorphone—PTGS1—Biological oxidations—CYP3A4—bone cancer	5.56e-05	0.00508	CbGpPWpGaD
Hydromorphone—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	5.55e-05	0.00508	CbGpPWpGaD
Hydromorphone—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	5.5e-05	0.00503	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR ligand binding—GRM1—bone cancer	5.39e-05	0.00492	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR ligand binding—SMO—bone cancer	5.12e-05	0.00468	CbGpPWpGaD
Hydromorphone—PTGS1—Biological oxidations—GSTP1—bone cancer	4.76e-05	0.00435	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR downstream signaling—GRM4—bone cancer	4.74e-05	0.00433	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR downstream signaling—RGS1—bone cancer	4.74e-05	0.00433	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR ligand binding—SMO—bone cancer	4.49e-05	0.00411	CbGpPWpGaD
Hydromorphone—OPRM1—TCR Signaling Pathway—JUN—bone cancer	4.48e-05	0.00409	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—GRM4—bone cancer	4.3e-05	0.00393	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—RGS1—bone cancer	4.3e-05	0.00393	CbGpPWpGaD
Hydromorphone—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	4.21e-05	0.00385	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR downstream signaling—GRM4—bone cancer	4.15e-05	0.0038	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR downstream signaling—RGS1—bone cancer	4.15e-05	0.0038	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR downstream signaling—GRM1—bone cancer	4.11e-05	0.00375	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—NDUFA12—bone cancer	4.09e-05	0.00374	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR ligand binding—SMO—bone cancer	3.8e-05	0.00347	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—GRM4—bone cancer	3.77e-05	0.00345	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—RGS1—bone cancer	3.77e-05	0.00345	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—GRM1—bone cancer	3.73e-05	0.00341	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR downstream signaling—GRM1—bone cancer	3.6e-05	0.00329	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—GRM4—bone cancer	3.51e-05	0.00321	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—RGS1—bone cancer	3.51e-05	0.00321	CbGpPWpGaD
Hydromorphone—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	3.48e-05	0.00318	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—NT5C3A—bone cancer	3.39e-05	0.0031	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—NDUFA12—bone cancer	3.33e-05	0.00305	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—GRM1—bone cancer	3.27e-05	0.00299	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—GRM4—bone cancer	3.19e-05	0.00291	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—RGS1—bone cancer	3.19e-05	0.00291	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—GRM1—bone cancer	3.04e-05	0.00278	CbGpPWpGaD
Hydromorphone—CYP2D6—Biological oxidations—CYP3A4—bone cancer	2.95e-05	0.0027	CbGpPWpGaD
Hydromorphone—CYP2C9—Biological oxidations—CYP3A4—bone cancer	2.92e-05	0.00267	CbGpPWpGaD
Hydromorphone—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	2.91e-05	0.00266	CbGpPWpGaD
Hydromorphone—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	2.88e-05	0.00264	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—GRM1—bone cancer	2.76e-05	0.00253	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—NT5C3A—bone cancer	2.76e-05	0.00253	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR downstream signaling—GNA11—bone cancer	2.65e-05	0.00242	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—SMO—bone cancer	2.63e-05	0.0024	CbGpPWpGaD
Hydromorphone—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.55e-05	0.00233	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—GRM4—bone cancer	2.54e-05	0.00232	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—RGS1—bone cancer	2.54e-05	0.00232	CbGpPWpGaD
Hydromorphone—CYP2D6—Biological oxidations—GSTP1—bone cancer	2.52e-05	0.00231	CbGpPWpGaD
Hydromorphone—CYP2C9—Biological oxidations—GSTP1—bone cancer	2.5e-05	0.00229	CbGpPWpGaD
Hydromorphone—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	2.49e-05	0.00227	CbGpPWpGaD
Hydromorphone—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	2.47e-05	0.00225	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—GNA11—bone cancer	2.4e-05	0.0022	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR downstream signaling—IL3—bone cancer	2.4e-05	0.00219	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR downstream signaling—GNA11—bone cancer	2.32e-05	0.00212	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—SMO—bone cancer	2.3e-05	0.00211	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—GRM4—bone cancer	2.23e-05	0.00204	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—RGS1—bone cancer	2.23e-05	0.00204	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—GRM1—bone cancer	2.2e-05	0.00201	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—IL3—bone cancer	2.18e-05	0.00199	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—GNA11—bone cancer	2.11e-05	0.00193	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR downstream signaling—IL3—bone cancer	2.1e-05	0.00192	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—GNA11—bone cancer	1.96e-05	0.00179	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—SMO—bone cancer	1.95e-05	0.00178	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—GRM1—bone cancer	1.93e-05	0.00177	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—IL3—bone cancer	1.91e-05	0.00175	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—GRM4—bone cancer	1.88e-05	0.00172	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—RGS1—bone cancer	1.88e-05	0.00172	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—GNA11—bone cancer	1.78e-05	0.00163	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—IL3—bone cancer	1.78e-05	0.00163	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—NDUFA12—bone cancer	1.77e-05	0.00162	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—NDUFA12—bone cancer	1.75e-05	0.0016	CbGpPWpGaD
Hydromorphone—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.65e-05	0.00151	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—GRM1—bone cancer	1.63e-05	0.00149	CbGpPWpGaD
Hydromorphone—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.63e-05	0.00149	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—IL3—bone cancer	1.62e-05	0.00148	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—SMO—bone cancer	1.55e-05	0.00142	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—ENO2—bone cancer	1.48e-05	0.00136	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—NT5C3A—bone cancer	1.46e-05	0.00134	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—NT5C3A—bone cancer	1.45e-05	0.00133	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—GNA11—bone cancer	1.42e-05	0.0013	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—DHFR—bone cancer	1.38e-05	0.00126	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—SMO—bone cancer	1.36e-05	0.00124	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—ATF1—bone cancer	1.32e-05	0.00121	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—IL3—bone cancer	1.29e-05	0.00118	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—GNA11—bone cancer	1.29e-05	0.00118	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—GNA11—bone cancer	1.25e-05	0.00114	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—ENO2—bone cancer	1.21e-05	0.00111	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—CYP3A4—bone cancer	1.17e-05	0.00107	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.16e-05	0.00106	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—ATF1—bone cancer	1.16e-05	0.00106	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NDUFA12—bone cancer	1.16e-05	0.00106	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—SMO—bone cancer	1.15e-05	0.00105	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—IL3—bone cancer	1.13e-05	0.00103	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—DHFR—bone cancer	1.12e-05	0.00103	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—TGFBR2—bone cancer	1.1e-05	0.00101	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—GNA11—bone cancer	1.05e-05	0.000962	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—GNA11—bone cancer	1.05e-05	0.000959	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—IGF1R—bone cancer	1.04e-05	0.000947	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—GSTP1—bone cancer	9.98e-06	0.000912	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—ATF1—bone cancer	9.78e-06	0.000894	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—TGFBR2—bone cancer	9.65e-06	0.000883	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NT5C3A—bone cancer	9.58e-06	0.000876	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—IL3—bone cancer	9.54e-06	0.000872	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—CYP3A4—bone cancer	9.51e-06	0.000869	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.46e-06	0.000865	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—IGF1R—bone cancer	9.08e-06	0.00083	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—TGFBR2—bone cancer	8.16e-06	0.000746	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—GSTP1—bone cancer	8.14e-06	0.000744	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—IGF1R—bone cancer	7.68e-06	0.000702	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—KIT—bone cancer	7.51e-06	0.000687	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—BRAF—bone cancer	7.06e-06	0.000646	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—EGFR—bone cancer	6.85e-06	0.000626	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—KIT—bone cancer	6.59e-06	0.000602	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—ENO2—bone cancer	6.42e-06	0.000587	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—ENO2—bone cancer	6.36e-06	0.000581	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—BRAF—bone cancer	6.19e-06	0.000566	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—EGFR—bone cancer	6e-06	0.000549	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—DHFR—bone cancer	5.95e-06	0.000544	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—MDM2—bone cancer	5.92e-06	0.000541	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—DHFR—bone cancer	5.9e-06	0.000539	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—KIT—bone cancer	5.57e-06	0.000509	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—GNA11—bone cancer	5.56e-06	0.000509	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—GNA11—bone cancer	5.52e-06	0.000504	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—BRAF—bone cancer	5.23e-06	0.000478	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MDM2—bone cancer	5.19e-06	0.000474	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PTGS2—bone cancer	5.17e-06	0.000473	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—JUN—bone cancer	5.14e-06	0.00047	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—EGFR—bone cancer	5.07e-06	0.000464	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CYP3A4—bone cancer	5.04e-06	0.000461	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—MMP9—bone cancer	5e-06	0.000457	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CYP3A4—bone cancer	5e-06	0.000457	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.98e-06	0.000455	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—JUN—bone cancer	4.51e-06	0.000412	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—MMP9—bone cancer	4.39e-06	0.000401	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MDM2—bone cancer	4.39e-06	0.000401	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—GSTP1—bone cancer	4.31e-06	0.000394	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—GSTP1—bone cancer	4.28e-06	0.000391	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PTGS2—bone cancer	4.21e-06	0.000385	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—ENO2—bone cancer	4.2e-06	0.000383	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—EGFR—bone cancer	4.04e-06	0.00037	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—DHFR—bone cancer	3.89e-06	0.000356	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—JUN—bone cancer	3.81e-06	0.000348	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—MMP9—bone cancer	3.71e-06	0.000339	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GNA11—bone cancer	3.64e-06	0.000333	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—EGFR—bone cancer	3.55e-06	0.000324	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—TP53—bone cancer	3.4e-06	0.00031	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—EGFR—bone cancer	3e-06	0.000274	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—TP53—bone cancer	2.98e-06	0.000272	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—GSTP1—bone cancer	2.82e-06	0.000258	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—TP53—bone cancer	2.52e-06	0.00023	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PTGS2—bone cancer	2.23e-06	0.000204	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PTGS2—bone cancer	2.22e-06	0.000203	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PTGS2—bone cancer	1.46e-06	0.000134	CbGpPWpGaD
